Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Pfizer: 3 Trades To Buy Into Cash Rich Pharma Giant

By Investing.com (Tezcan Gecgil/Investing.com )Stock MarketsJun 27, 2022 10:28AM ET
www.investing.com/analysis/pfizer-3-trades-to-buy-into-cash-rich-pharma-giant-200626315
Pfizer: 3 Trades To Buy Into Cash Rich Pharma Giant
By Investing.com (Tezcan Gecgil/Investing.com )   |  Jun 27, 2022 10:28AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
  • Shares of Pfizer are down over 12.5% since the start of 2022.
  • Plan to spend cash generated from COVID-19 vaccine on M&As and share buybacks.
  • Long-term investors may consider buying PFE stock at current levels.
  • Looking for more top-rated stock ideas to add to your portfolio? Members of InvestingPro+ get exclusive access to our research tools, data, and pre-selected screeners. Learn More »

Shareholders in Pfizer (NYSE:PFE) stock have seen the value of their investment increase over 32% in the past 52 weeks. However, PFE shares have declined 12.5% year-to-date (YTD).

By comparison, the Dow Jones Health Care is down roughly 10% in 2022. Meanwhile, two other major pharma shares, Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK), have gained 17.9% and 21.5%, respectively.

PFE Weekly
PFE Weekly

On Dec. 20, 2021, PFE shares went over $61, hitting a record high. The stock’s 52-week range has been $38.82-$61.71. The market capitalization (cap) currently stands at $289.5 billion.

How Recent Metrics Came

Pfizer released Q1 figures on May 3. Revenue totaled $25.7 billion, up 77% year-over-year (YoY). Adjusted net income was $9.3 billion, or $1.62 per diluted share, compared to an adjusted net income of $5.4 billion, or 95 cents per diluted share, a year ago.

Given its leading position in the coronavirus vaccine market, Pfizer is generating significant cash. Revenue and earnings have increased, thanks to Comirnaty, the COVID-19 vaccine offered jointly with BioNTech (NASDAQ:BNTX).

In December 2021, the US Food and Drug Administration (FDA) also authorized Paxlovid “for the treatment of mild-to-moderate COVID-19.” The healthcare giant generated $31.78 billion in free cash flow during the first quarter, representing a 50% increase YoY.

On the results, chief financial officer Frank D’Amelio commented:

“We entered the open market to repurchase shares of our stock for the first time since 2019. We will continue to thoughtfully deploy our capital in a variety of shareholder-friendly ways with the goal of maximizing the value we provide to all of our stakeholders, including patients and shareholders.”

Pfizer has recently ramped up its M&A activity, fueled by its growing pile of cash. For example, in March it bought Arena Pharmaceuticals for $6.7 billion in cash. This transaction adds a number of pipeline candidates that target immuno-inflammatory diseases.

Then, in early June, Pfizer also completed the acquisition of ReViral, a privately held clinical-stage biopharmaceutical company focused on therapies for the respiratory syncytial virus. While Pfizer currently relies on its coronavirus portfolio for growth, these new names are primed to boost long-term growth.

After the release of Q1 results, Pfizer kept its previous revenue guidance unchanged within the $98-$102 billion range. On the other hand, diluted EPS guidance was revised down from the previous $6.35-$6.55 range to $6.25-$6.45.

Prior to the release of the Q1 results, PFE stock was around $49.00. On June 24, it closed at $51.59, and offers a dividend yield of 3.1%.

What To Expect From Pfizer Stock

PFE stock has an "outperform" rating among 22 analysts polled via Investing.com. Wall Street has a 12-month median price target of $57.26 for the stock, an increase of 11% from the current price. The 12-month price range currently stands between $46 and $75.

PFE Consensus Estimates
PFE Consensus Estimates

Source: Investing.com

Similarly, according to a number of valuation models including P/E or P/S multiples or terminal values, the average fair value for PFE stock on InvestingPro stands at $70.52.

PFE Fair Value
PFE Fair Value

Source: InvestingPro

So fundamental valuation suggests shares could increase 36.7%.

Examining PFE’s financial health in terms of growth, price momentum, and profit, it scores 4 out of 5. Its overall score of 4 points is a great performance ranking.

At present, PFE’s P/E, P/B and P/S ratios are 11.4x, 3.5x and 3.1x, respectively compared to 17.7x, 4.9x and 3.9x respectively for peers which suggest that fundamentally it looks undervalued compared to healthcare peers.

We expect PFE stock to build a base between $48 and $53 in the coming weeks and then potentially start a new leg up.

Adding PFE Stock To Portfolios

Pfizer bulls who are not concerned about short-term volatility could consider investing now with a target of $57.26, as per Wall Street analysts.

Alternatively, investors could consider buying an exchange-traded fund (ETF) that has PFE stock as a holding. Examples include:

  • iShares U.S. Pharmaceuticals ETF (NYSE:IHE)
  • First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL)
  • Health Care Select Sector SPDR® Fund (NYSE:XLV)
  • Vanguard S&P 500 ETF (NYSE:VOO)
  • ETC 6 Meridian Hedged Equity-Index Option Strategy ETF (NYSE:SIXH)

Finally, those experienced with options could also consider selling a cash-secured put option in PFE stock—a strategy we regularly cover. Such a bullish trade could especially appeal to those who want to receive premiums (from put selling) or to possibly own PFE shares for less than their current market price of $51.59.

Most option strategies are not suitable for all retail investors. Therefore, the following discussion on PFE stock is offered for educational purposes and not as an actual strategy to be followed by the average retail investor.

So the trader would typically write an at-the-money (ATM) or an out-of-the-money (OTM) put option and simultaneously set aside enough cash to buy 100 shares of the stock.

Let's assume the trader is putting on this trade until the option expiry date of August 19. As the stock is $51.45 at time of writing, an OTM put option would have a strike of $50.00. This put option is currently offered at a price (or premium) of $1.85.

An option buyer would have to pay $1.85 X 100, or $185, in premium to the option seller. This premium amount belongs to the option seller no matter what happens in the future and also it is the seller’s maximum gain. The put option will stop trading on Friday, August 19.

If the put option is in the money (meaning the market price of PFE stock is lower than the strike price of $50.00) any time before or at expiration on Aug. 19, this put option can be assigned. The seller would then be obligated to buy 100 shares of PFE stock at the put option's strike price of $50.00 (i.e. at a total of $4,750).

The break-even point for our example is the strike price ($50.00) less the option premium received ($1.85), i.e., $48.15. This is the price at which the seller would start to incur a loss.

Bottom Line

Cash-secured put selling is a moderately more conservative strategy than buying shares outright at the current market price. It could be a way to capitalize on the choppiness in PFE stock in the coming weeks.

Investors who end up owning Pfizer as a result of selling puts could further consider setting up covered calls to increase the potential returns on their shares. Thus, selling cash-secured puts could be regarded as the first step in PFE stock ownership.

***

The current market makes it harder than ever to make the right decisions. Think about the challenges:

  • Inflation
  • Geopolitical turmoil
  • Disruptive technologies
  • Interest rate hikes

To handle them, you need good data, effective tools to sort through the data, and insights into what it all means. You need to take emotion out of investing and focus on the fundamentals.

For that, there’s InvestingPro+, with all the professional data and tools you need to make better investing decisions. Learn More »

Pfizer: 3 Trades To Buy Into Cash Rich Pharma Giant
 

Related Articles

Pfizer: 3 Trades To Buy Into Cash Rich Pharma Giant

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Pa Sak
Pa Sak Jun 27, 2022 1:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Posso Ganhar Dinheiro?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email